Resting State Electroencephalogram for Psychotic Disorders

Sponsor
Central South University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05065489
Collaborator
(none)
200
Enrollment
1
Location
15
Anticipated Duration (Months)
13.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Electroencephalography (EEG) has been proposed as a neurophysiological biomarker to delineate psychotic disorders. Meanwhile, the increased appetite, which might related to self-control process, has been an increasing concern for the management of psychotic disorders. In this cross-section study, investigators collect the resting state EEG data, self-control related scale, eating behaviour questionnaire and psychotic syndrome related assessement and try to find the connection between those measurers, in order to provide novel understanding on the mechanism of psychotic diseases.

Condition or DiseaseIntervention/TreatmentPhase
  • Other: No intervention

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Self-control, Appetite and Psychotic Diagnose: a Resting State EEG Cross Section Study
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Schizophrenia patients

patients who diagnosed with schizophrenia in accordance with DSM-5 criteria

Other: No intervention
No intervention

Bipolar disorder patients

patients who diagnosed with bipolar disorder in accordance with DSM-5 criteria

Other: No intervention
No intervention

Depression patients

patients who diagnosed with major depression disorder in accordance with DSM-5 criteria

Other: No intervention
No intervention

Health control

health participants who have not diagnosed with any psychological or psychiatric disease.

Other: No intervention
No intervention

Outcome Measures

Primary Outcome Measures

  1. resting state EEG [baseline]

    resting state electroencephalography

Secondary Outcome Measures

  1. Three factor eating questionnaire [baseline]

    min value 21, max value 84. The higher scores mean more unhealthy eating behavior.

  2. Barratt Impulsivity Scale [baseline]

    min score 26, max score 104. The higher score means more impulsive.

  3. Self-Control Scale [baseline]

    min score 36, max score 180. The higher score means less self control.

  4. The positive and negative syndrome scale [baseline]

    min score 30, max score 210. The higher score means more severe symptoms.

  5. Hamilton anxiety rating scale [baseline]

    min score 14, max score 56. The higher score means more severe anxiety symptom

  6. Hamilton depression rating scale [baseline]

    min score 17, max score 68. The higher score means more severe depressive symptom

  7. Young manic rating scale [baseline]

    min score 0, max score 60, the higher score means more severe manic syndrome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Diagnosed with schizophrenia or bipolar disorder or MDD in accordance with DMS-5 Informed Consent

Exclusion Criteria:

Diagnosed with other mental disease in accordance with DSM-5 Comorbid with other severe physiological disease Drug or alcohol abuse Pregnant or lactating

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Mental Health Institute of 2nd Xiangya Hospital,CSUChangshaHunanChina410011

Sponsors and Collaborators

  • Central South University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Renrong Wu,PhD, Professor, Central South University
ClinicalTrials.gov Identifier:
NCT05065489
Other Study ID Numbers:
  • WU2021EEG
First Posted:
Oct 4, 2021
Last Update Posted:
Oct 13, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Renrong Wu,PhD, Professor, Central South University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 13, 2021